Small molecule · developed by Verastem
PF00562271 is a tablet taken at 125 mg twice daily with food. It is studied in head and neck neoplasms, prostatic neoplasms and pancreatic neoplasms.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00666926 | Phase 1 | Head and Neck Neoplasm | Completed | VSTM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Head and Neck NeoplasmPancreatic NeoplasmProstatic Neoplasm
Updated Nov 1, 2026. Something wrong or missing? Report it on the VSTM page.
See VSTM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
VSTM catalysts and pipeline →